Impact of plasma HIV-1 RNA reduction on HIV-1 incidence and infections averted in high versus low incidence cohorts.

1High and low incidence populations include the subset of clinical trial sites with the highest and lowest HIV-1 incidence, respectively.
2The log-linear model is used to estimate HIV-1 infections averted per year as the difference in HIV-1 infections that would occur in that plasma RNA stratum if the plasma HIV-1 RNA reduction is applied to a population of 100,000 HIV-1 uninfected persons compared to the number of HIV-1 infections expected in that population in the absence of the plasma HIV-1 RNA reduction. The total number of new HIV-1 infections expected per year in these hypothetical examples are 5800 and 1800 for the high and low incidence populations, respectively.